https://socictopen.socict.org/files/original/a7713b9f1ada8d8b50bbc8b85ae23c0a.pdf e8ca22ab217e6f30a0595347322d7ddd Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Reduced Prescription of Baloxavir After Suspected Prevalence of a Baloxavir-Resistant Influenza Virus Strain and the Emergence of SARS-CoV-2 in a Tertiary Hospital in Japan Creator An entity primarily responsible for making the resource Kamioka Y, Kashiwagura S, Seki M Description An account of the resource Yasuhiro Kamioka,1,2 Shota Kashiwagura,1,2 Masafumi Seki1 1Department of Infectious Diseases, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai City, Miyagi, Japan; 2Division of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai City, Miyagi, JapanCorrespondence: Masafumi SekiDepartment of Infectious Diseases, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, 1-15-1 Fukumuro, Miyagino-Ku, Sendai City, Miyagi 983-8612, JapanTel +81-22-259-1221Fax +81-22-290-8956Email m-seki@tohoku-mpu.ac.jpObjective: The use of baloxavir, a new anti-influenza agent, began in Japan from the 2018 to 2019 season and became the focus of attention due to its efficient viral reduction ability; therefore, we should know the prescription changes of anti-influenza agents.Methods: We analyzed the changes in the prescription of anti-influenza agents between the 2018– 19 season and the 2019– 20 season in our hospital.Results: The share of baloxavir was 15%, while the shares of oseltamivir and laninamivir were 42% and 31%, respectively in the 2018– 2019 season. However, in the 2019– 20 season, the share of baloxavir and laninamivir was reduced to 3% and 17%, respectively, in contrast to an increase in the share of oseltamivir (66%). The total prescription of anti-influenza agents for patients decreased in the 2019– 20 season (205 patients), compared with the 2018– 19 season (509 patients).Conclusion: These results suggest significant changes such as a reduction in the prescription of anti-influenza agents, especially baloxavir, likely due to the suspected prevalence of a baloxavir-resistant strain of influenza virus and the emergence of SARS-CoV-2 in Japan.Keywords: anti-influenza agents, oseltamivir, laninamivir, zanamivir, peramivir, novel coronavirus-2019, COVID-19 Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource oseltamivir, Peramivir, zanamivir, Laninamivir, anti-influenza agents, novel coronavirus-2019 (covid-19) Source A related resource from which the described resource is derived Biotemas Publisher An entity responsible for making the resource available Universidade Federal de Santa Catarina Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Therapeutics. Pharmacology